Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

4.180 -0.020 (-0.48%)
Streaming Delayed Price Updated: 12:40 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123,094
Open 4.170
Bid (Size) 4.180 (3)
Ask (Size) 4.190 (1)
Prev. Close 4.200
Today's Range 4.065 - 4.190
52wk Range 3.520 - 11.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-20.53%
-20.53%
1 Month
-30.33%
-30.33%
3 Month
-19.77%
-19.77%
6 Month
+8.85%
+8.85%
1 Year
-55.77%
-55.77%

More News

Read More
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
Via The Motley Fool
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Via Benzinga
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
Via News Direct
Exposures Product Safety
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
MarketBeat Week in Review – 7/17 - 7/21
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Acumen Announces Pricing of Upsized $130 Million Public Offering
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Via Benzinga
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.